1. Immune checkpoint inhibitors in the posttransplant landscape of HCC: A systematic literature review
   Doga Kahramangil et al, 2024, Liver Transplantation CrossRef
2. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
   Kazumasa Yamamoto et al, 2024, Expert Opinion on Drug Safety CrossRef
3. Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy
   Yoichi Hamai et al, 2024, Cancers CrossRef
4. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
   Ye Tao et al, 2023, Frontiers in Oncology CrossRef
5. Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
   Csaba Kerepesi et al, 2024, JCO Precision Oncology CrossRef
6. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
   Zhengfeng Zhang et al, 2023, Therapeutic Advances in Medical Oncology CrossRef